• 1
    Munkholm P, Langholz E, Davidsen M, Binder V. Frequency of glucocorticoid resistance and dependency in Crohn's disease. Gut 1994; 35: 3602.
  • 2
    Pearson DC, May GR, Fick G, Sutherland LR. Azathioprine for maintaining remission of Crohn's disease. Cochrane Database Syst Rev 2000; (2): CD0000 67.
  • 3
    Fraser AG, Orchard TR, Jewell DP. The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30 year review. Gut 2002; 50: 4859.
  • 4
    Sandborn W, Sutherland L, Pearson D, May G, Modigliani R, Prantera C. Azathioprine or mercaptopurine for inducing remission of Crohn's disease. Cochrane Database Syst Rev 2000; (2): CD000 45.
  • 5
    Schwab M, Schaeffeler E, Marx C, Zanger U, Aulitzky W, Eichelbaum M. Shortcoming in the diagnosis of TPMT deficiency in a patient with Crohn's disease using phenotyping only. Gastroenterology 2001; 121: 4989.
  • 6
    Dubinsky MC, Yang H, Hassard PV, et al. 6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease. Gastroenterology 2002; 122: 90415.
  • 7
    Lancaster DL, Lennard L, Rowland K, Vora AJ, Lilleyman JS. Thioguanine versus mercaptopurine for therapy of childhood lymphoblastic leukaemia: a comparison of haematological toxicity and drug metabolite concentrations. Br J Haematol 1998; 102: 43943.
  • 8
    Erb N, Harms DO, Janka-Schaub G. Pharmacokinetics and metabolism of thiopurines in children with acute lymphoblastic leukemia receiving 6-thioguanine versus mercaptopurine. Cancer Chemother Pharmacol 1998; 42: 26672.
  • 9
    Dubinsky MC, Hassard PV, Seidman EG, et al. An open-label pilot study using thioguanine as a therapeutic alternative in Crohn's disease patients resistant to mercaptopurine therapy. Inflamm Bowel Dis 2001; 7: 1819.
  • 10
    Kroplin T, Weyer N, Gutsche S, Iven H. Thiopurine S-methyltransferase activity in human erythrocytes: a new HPLC method using 6-thioguanine as substrate. Eur J Clin Pharmacol 1998; 54: 26571.
  • 11
    Schwab M, Schaffeler E, Marx C, et al. Azathioprine therapy and adverse drug reactions in patients with inflammatory bowel disease: impact of thiopurine S-methyltransferase polymorphism. Pharmacogenetics 2002; 12: 42936.
  • 12
    Sandborn WJ, Tremaine WJ, Wolf DC, et al. Lack of effect of intravenous administration on time to respond to azathioprine for steroid-treated Crohn's disease. North American Azathioprine Study Group. Gastroenterology 1999; 117: 52735.
  • 13
    Feagan BG, Rochon J, Fedorak RN, et al. Methotrexate for the treatment of Crohn's disease. The North American Crohn's Study Group Investigators. N Engl J Med 1995; 332: 2927.
  • 14
    Targan SR, Hanauer SB, Van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 1997; 337: 102935.
  • 15
    Present DH, Meltzer SJ, Krumholz MP, Wolke A, Korelitz BI. Mercaptopurine in the management of inflammatory bowel disease: short- and long-term toxicity. Ann Intern Med 1989; 111: 6419.
  • 16
    Bouhnik Y, Lemann M, Mary JY, et al. Long-term follow-up of patients with Crohn's disease treated with azathioprine or mercaptopurine. Lancet 1996; 347: 2159.
  • 17
    Connell WR, Kamm MA, Ritchie JK, Lennard-Jones JE. Bone marrow toxicity caused by azathioprine in inflammatory bowel disease: 27 years of experience. Gut 1993; 34: 10815.
  • 18
    Szumlanski CL, Weinshilboum RM. Sulphasalazine inhibition of thiopurine methyltransferase: possible mechanism for interaction with mercaptopurine and azathioprine. Br J Clin Pharmacol 1995; 39: 4569.
  • 19
    Lowry PW, Szumlanski CL, Weinshilboum RM, Sandborn WJ. Balsalazide and azathioprine or mercaptopurine: evidence for a potentially serious drug interaction. Gastroenterology 1999; 116: 15056.
  • 20
    Lowry PW, Franklin CL, Weaver AL, et al. Leucopenia resulting from a drug interaction between azathioprine or 6-mercaptopurine and mesalamine, sulphasalazine, or balsalazide. Gut 2001; 49: 65664.
  • 21
    Key NS, Kelly PM, Emerson PM, Chapman RW, Allan NC, McGee JO. Oesophageal varices associated with busulphan–thioguanine combination therapy for chronic myeloid leukaemia. Lancet 1987; 2: 10502.
  • 22
    Shepherd PC, Fooks J, Gray R, Allan NC. Thioguanine used in maintenance therapy of chronic myeloid leukaemia causes non-cirrhotic portal hypertension. Results from MRC CML. II. Trial comparing busulphan with busulphan and thioguanine. Br J Haematol 1991; 79: 18592.
  • 23
    Stork LC, Broxson EH, Sather H, et al. Oral 6-thioguanine causes late-onset splenomegaly and portal hypertension in a subset of children with acute lymphoblastic leukemia. Gastroenterology 2002; 122: 189.